Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
A Comprehensive Review of Nepafenac's R&D Innovations and Drug Target Mechanism
10 November 2023
This article summarized the latest R&D progress of Nepafenac, the Mechanism of Action for Nepafenac, and the drug target R&D trends for Nepafenac.
Latest Hotspot
3 min read
The phase 2 clinical trial results of MoonLake's innovative nanobody treatment, Sonelokimab, have shown positive outcomes, effectively alleviating psoriasis
10 November 2023
MoonLake Immunotherapeutics recently announced positive results from the global Phase 2 clinical trial, ARGO, assessing the efficacy and safety of its nanobody, sonelokimab, in patients with active psoriatic arthritis (PsA).
Drug Insights
4 min read
Pharmaceutical Insights: Nemolizumab's R&D Progress and its Mechanism of Action on Drug Target
10 November 2023
This article summarized the latest R&D progress of Nemolizumab, the Mechanism of Action for Nemolizumab, and the drug target R&D trends for Nemolizumab.
Advanced Tech.
6 min read
Highly Efficient Treatment for Killing Drug-Resistant Bacteria: Bacteriophage Therapy
10 November 2023
Challenging the pathogenicity of bacteria through Bacteriophage therapy could lead the way to improved antibiotic strategies.
Drug Insights
5 min read
ExploringMycophenolate Sodium's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
10 November 2023
This article summarized the latest R&D progress of Mycophenolate Sodium, the mechanism of action for Mycophenolate Sodium, and the drug target R&D trends for Mycophenolate Sodium.
Valuable Targets
6 min read
New Generation Vaccine Adjuvant: TLR Agonists
10 November 2023
TLRs are innate immune receptors that are responsible, directly or indirectly, for detecting pathogen-associated molecular patterns (PAMPs) and responding to them through the activation of innate and adaptive immune pathways.
Latest Hotspot
3 min read
Molecular Templates has begun Phase 1 dosing of MT-8421, a distinct engineered toxin body targeting CTLA-4, for advanced solid tumor treatment
10 November 2023
Molecular Templates has commenced dosing in Phase 1 trial of MT-8421, a unique engineered toxin body targeting CTLA-4, for treating advanced solid tumors.
Drug Insights
4 min read
Decoding Naftifine Hydrochloride: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
10 November 2023
This article summarized the latest R&D progress of Naftifine Hydrochloride, the Mechanism of Action for Naftifine Hydrochloride, and the drug target R&D trends for Naftifine Hydrochloride.
Latest Hotspot
3 min read
TTerns Pharmaceuticals announced first participant treatment in Phase 1 Trials of potential obesity drug TERN-601 Oral GLP-1 Receptor Agonist
9 November 2023
TTerns Pharmaceuticals reported the initial participant administration in Phase 1 Clinical Testing of TERN-601 Oral GLP-1 Receptor Agonist, a potential treatment for obesity.
Advanced Tech.
5 min read
Hot Track in Disease Treatment: Mesenchymal Stem Cell Therapy
9 November 2023
Mesenchymal stem cells (MSCs) have broad therapeutic potential for treating inflammation and degenerative diseases.
Drug Insights
4 min read
Deep Scientific Insights on Naloxegol Oxalate's R&D Progress, Mechanism of Action, and Drug Target
9 November 2023
This article summarized the latest R&D progress of Naloxegol Oxalate, the Mechanism of Action for Naloxegol Oxalate, and the drug target R&D trends for Naloxegol Oxalate.
Valuable Targets
9 min read
Analysis on the Research Progress of Endothelin Receptor Antagonist
9 November 2023
Endothelin receptor are G protein-coupled receptors (GPCRs) of the β-group of rhodopsin receptors that bind to endothelin ligands, which are 21 amino acid long peptides derived from longer prepro-endothelin precursors.